CSIMarket
 

Chemocentryx Inc.  (NASDAQ: CCXI)

Chemocentryx Inc's

Competitiveness




 

CCXI Sales vs. its Competitors Q2 2022







Revenue Growth Comparisons




Net Income Comparison




<<  CCXI Stock Performance Comparisons



*Market share is calculated based on total revenue.





Publicly Traded Peers of Chemocentryx Inc.




Immuron Limited
Share Performance



-37.10%
One Year



Immuron Limited
Profile

Immuron Limited's business model involves the development and commercialization of oral immunotherapeutics that target and treat various diseases.

More about Immuron Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ 6.765 mill. $ -5.216 mill.

Sources: Chemocentryx Inc.’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Chemocentryx Inc. versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.